

# Michelle M Mello

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8558864/publications.pdf>

Version: 2024-02-01

205  
papers

10,401  
citations

31902

53  
h-index

40881

93  
g-index

206  
all docs

206  
docs citations

206  
times ranked

9276  
citing authors

#	ARTICLE	IF	CITATIONS
1	Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncology. <i>Cancer</i> , 2022, 128, 275-283.	2.0	5
2	U.S. Public Health Law â€” Foundations and Emerging Shifts. <i>New England Journal of Medicine</i> , 2022, 386, 805-808.	13.9	6
3	Vaccine Misinformation and the First Amendmentâ€™The Price of Free Speech. <i>JAMA Health Forum</i> , 2022, 3, e220732.	1.0	5
4	Incentives for COVID-19 vaccination. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100205.	1.5	17
5	Population health science as a unifying foundation for translational clinical and public health research. <i>SSM - Population Health</i> , 2022, 18, 101047.	1.3	3
6	Assessment of Perioperative Outcomes Among Surgeons Who Operated the Night Before. <i>JAMA Internal Medicine</i> , 2022, 182, 720.	2.6	10
7	Protecting the Privacy of Reproductive Health Information After the Fall of <i>Roe v Wade</i> . <i>JAMA Health Forum</i> , 2022, 3, e222656.	1.0	18
8	Apology laws and malpractice liability: what have we learned?. <i>BMJ Quality and Safety</i> , 2021, 30, 64-67.	1.8	5
9	When Physicians Engage in Practices That Threaten the Nationâ€™s Health. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 723.	3.8	7
10	Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after <i>United States v. Caronia</i> : An Analysis of Litigated Cases. <i>Journal of Health Politics, Policy and Law</i> , 2021, 46, 487-504.	0.9	3
11	To Address Drug Affordability, Grab the Low-Hanging Fruit. <i>JAMA Health Forum</i> , 2021, 2, e210260.	1.0	0
12	How US law will evaluate artificial intelligence for covid-19. <i>BMJ, The</i> , 2021, 372, n234.	3.0	8
13	Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. <i>Lancet, The</i> , 2021, 397, 1165-1167.	6.3	25
14	Choices in a Crisis â€” Individual Preferences among SARS-CoV-2 Vaccines. <i>New England Journal of Medicine</i> , 2021, 384, e62.	13.9	14
15	To Address Drug Affordability, Grab the Low-hanging Fruit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1599.	3.8	2
16	Supporting Hospitals During a New Wave of COVID-19. <i>Journal of Hospital Medicine</i> , 2021, 16, 311-312.	0.7	0
17	Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs. <i>JAMA Network Open</i> , 2021, 4, e217075.	2.8	24
18	The Medical Liability Environment: Is It Really Any Worse for Hospitalists?. <i>Journal of Hospital Medicine</i> , 2021, 16, 446.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Drug Pricing Reform in 2021â€”Going Big or Going Bipartisan?. JAMA Health Forum, 2021, 2, e212372.	1.0	2
20	Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis. BMJ Open, 2021, 11, e053248.	0.8	8
21	Incorporating Health Equity Into COVID-19 Reopening Plans: Policy Experimentation in California. American Journal of Public Health, 2021, 111, 1481-1488.	1.5	12
22	Public Health Law after Covid-19. New England Journal of Medicine, 2021, 385, 1153-1155.	13.9	13
23	The Political and Judicial Battles Over Mask Mandates for Schools. JAMA Health Forum, 2021, 2, e214192.	1.0	1
24	Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet, The, 2021, 398, 2186-2192.	6.3	106
25	Barriers to Ensuring Access to Affordable Prescription Drugs. Annual Review of Pharmacology and Toxicology, 2020, 60, 275-289.	4.2	5
26	The Missing Piece â€” SARS-CoV-2 Testing and School Reopening. New England Journal of Medicine, 2020, 383, e126.	13.9	24
27	Narrowing Vaccination Exemption Laws: Lessons From California and Beyond. Annals of Internal Medicine, 2020, 172, 358.	2.0	3
28	Partitioning the Curve â€” Interstate Travel Restrictions During the Covid-19 Pandemic. New England Journal of Medicine, 2020, 383, e83.	13.9	22
29	Attacks on Public Health Officials During COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 741.	3.8	58
30	Ensuring successful implementation of communication-and-resolution programmes. BMJ Quality and Safety, 2020, 29, 895-904.	1.8	11
31	Respecting Disability Rights â€” Toward Improved Crisis Standards of Care. New England Journal of Medicine, 2020, 383, e26.	13.9	44
32	Ethics and governance for digital disease surveillance. Science, 2020, 368, 951-954.	6.0	87
33	The Legal Authority for Statesâ€™ Stay-at-Home Orders. New England Journal of Medicine, 2020, 383, e29.	13.9	10
34	Diagnostic Testing for the Novel Coronavirus. JAMA - Journal of the American Medical Association, 2020, 323, 1437.	3.8	209
35	Standing Up against Gender Bias and Harassment â€” A Matter of Professional Ethics. New England Journal of Medicine, 2020, 382, 1385-1387.	13.9	28
36	Ensuring Uptake of Vaccines against SARS-CoV-2. New England Journal of Medicine, 2020, 383, 1296-1299.	13.9	77

#	ARTICLE	IF	CITATIONS
37	Waiting for data: Barriers to executing data use agreements. <i>Science</i> , 2020, 367, 150-152.	6.0	15
38	Malpractice Liability and Health Care Quality. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 352.	3.8	44
39	Thinking Globally, Acting Locally – The U.S. Response to Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, e75.	13.9	222
40	School Reopenings and the Community During the COVID-19 Pandemic. <i>JAMA Health Forum</i> , 2020, 1, e201294.	1.0	11
41	Oncologist experiences regarding patient-recorded clinical encounters: Implications for the patient-doctor relationship. <i>Journal of Clinical Oncology</i> , 2020, 38, 290-290.	0.8	0
42	Big Data, Big Tech, and Protecting Patient Privacy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1141.	3.8	85
43	Assessment of Out-of-Network Billing for Privately Insured Patients Receiving Care in In-Network Hospitals. <i>JAMA Internal Medicine</i> , 2019, 179, 1543.	2.6	50
44	The Role of Transparency in Patient Safety Improvement. , 2019, , 244-259.		0
45	Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. <i>BMJ: British Medical Journal</i> , 2019, 366, l4217.	2.4	40
46	Multilevel legal approaches to obesity prevention: A conceptual and methodological toolkit. <i>PLoS ONE</i> , 2019, 14, e0220971.	1.1	6
47	“Poking the skunk”: Ethical and medico-legal concerns in research about patients’ experiences of medical injury. <i>Bioethics</i> , 2019, 33, 948-957.	0.7	3
48	US Nationwide Disclosure of Industry Payments and Public Trust in Physicians. <i>JAMA Network Open</i> , 2019, 2, e191947.	2.8	40
49	Effect of the public disclosure of industry payments information on patients: results from a population-based natural experiment. <i>BMJ Open</i> , 2019, 9, e024020.	0.8	31
50	Changes in Practice among Physicians with Malpractice Claims. <i>New England Journal of Medicine</i> , 2019, 380, 1247-1255.	13.9	20
51	Association of Overlapping Surgery With Perioperative Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 762.	3.8	62
52	Association of Federal Mental Health Parity Legislation With Health Care Use and Spending Among High Utilizers of Services. <i>Medical Care</i> , 2019, 57, 245-255.	1.1	2
53	Legal Barriers to the Growth of Health Information Exchange—Boulders or Pebbles?. <i>Milbank Quarterly</i> , 2018, 96, 110-143.	2.1	63
54	Commentary: How Should Hospitals Respond to Surgeons’ Requests to Schedule Overlapping Surgeries?. <i>Neurosurgery</i> , 2018, 82, E91-E98.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Vaccination without Litigation â€” Addressing Religious Objections to Hospital Influenza-Vaccination Mandates. <i>New England Journal of Medicine</i> , 2018, 378, 785-788.	13.9	12
56	Disclosing Prescription-Drug Prices in Advertisements â€” Legal and Public Health Issues. <i>New England Journal of Medicine</i> , 2018, 379, 2290-2293.	13.9	5
57	Can Communication-And-Resolution Programs Achieve Their Potential? Five Key Questions. <i>Health Affairs</i> , 2018, 37, 1845-1852.	2.5	22
58	Effects Of A Communication-And-Resolution Program On Hospitalsâ€™ Malpractice Claims And Costs. <i>Health Affairs</i> , 2018, 37, 1836-1844.	2.5	32
59	Beyond financial conflicts of interest: Institutional oversight of faculty consulting agreements at schools of medicine and public health. <i>PLoS ONE</i> , 2018, 13, e0203179.	1.1	5
60	Ethics of randomized trials in a public health emergency. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006313.	1.3	12
61	HIPAA and Protecting Health Information in the 21st Century. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 231.	3.8	118
62	Behind Schedule â€” Reconciling Federal and State Marijuana Policy. <i>New England Journal of Medicine</i> , 2018, 379, 501-504.	13.9	20
63	What Patients Expect and Deserveâ€”Reply. <i>JAMA Internal Medicine</i> , 2018, 178, 578.	2.6	0
64	Clinical Trial Participantsâ€™ Views of the Risks and Benefits of Data Sharing. <i>New England Journal of Medicine</i> , 2018, 378, 2202-2211.	13.9	162
65	Association of Unsolicited Patient Observations With the Quality of a Surgeonâ€™s Care. <i>JAMA Surgery</i> , 2017, 152, 530.	2.2	0
66	Public Awareness of and Contact With Physicians Who Receive Industry Payments: A National Survey. <i>Journal of General Internal Medicine</i> , 2017, 32, 767-774.	1.3	62
67	Medical Liability â€” Prospects for Federal Reform. <i>New England Journal of Medicine</i> , 2017, 376, 1806-1808.	13.9	12
68	Improving reconciliation following medical injury: a qualitative study of responses to patient safety incidents in New Zealand. <i>BMJ Quality and Safety</i> , 2017, 26, 788-798.	1.8	34
69	Outcomes In Two Massachusetts Hospital Systems Give Reason For Optimism About Communication-And-Resolution Programs. <i>Health Affairs</i> , 2017, 36, 1795-1803.	2.5	25
70	In search of global governance for research in epidemics. <i>Lancet, The</i> , 2017, 390, 1632-1633.	6.3	6
71	Patientsâ€™ Experiences With Communication-and-Resolution Programs After Medical Injury. <i>JAMA Internal Medicine</i> , 2017, 177, 1595.	2.6	50
72	Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. <i>BMJ Open</i> , 2017, 7, e017917.	0.8	46

#	ARTICLE	IF	CITATIONS
73	Length of Stay After Overlapping Surgeryâ€™Reply. JAMA - Journal of the American Medical Association, 2017, 318, 2140.	3.8	0
74	Drug Companiesâ€™™ Liability for the Opioid Epidemic. New England Journal of Medicine, 2017, 377, 2301-2305.	13.9	54
75	The Evolving Story of Overlapping Surgery. JAMA - Journal of the American Medical Association, 2017, 318, 233.	3.8	31
76	When are primary care physicians untruthful with patients? A qualitative study. AJOB Empirical Bioethics, 2017, 8, 32-39.	0.8	3
77	Testing the Immunity of the Firearm Industry to Tort Litigation. JAMA Internal Medicine, 2017, 177, 102.	2.6	4
78	Association Between State Medical Malpractice Environment and Surgical Quality and Cost in the United States. Annals of Surgery, 2016, 263, 1126-1132.	2.1	16
79	Sociodemographic Predictors of Vaccination Exemptions on the Basis of Personal Belief in California. American Journal of Public Health, 2016, 106, 172-177.	1.5	62
80	Case Outcomes in a Communication-and-Resolution Program in New York Hospitals. Health Services Research, 2016, 51, 2583-2599.	1.0	15
81	Challenges of Implementing a Communicationâ€™andâ€™Resolution Program Where Multiple Organizations Must Cooperate. Health Services Research, 2016, 51, 2550-2568.	1.0	20
82	Building a National Surveillance System for Malpractice Claims. Health Services Research, 2016, 51, 2642-2648.	1.0	8
83	Collaboration with Regulators to Support Quality and Accountability Following Medical Errors: The Communication and Resolution Program Certification Pilot. Health Services Research, 2016, 51, 2569-2582.	1.0	11
84	Prevalence and Characteristics of Physicians Prone to Malpractice Claims. New England Journal of Medicine, 2016, 374, 354-362.	13.9	114
85	Managing the Risks of Concurrent Surgeries. JAMA - Journal of the American Medical Association, 2016, 315, 1563.	3.8	52
86	Have Tobacco 21 Laws Come of Age?. New England Journal of Medicine, 2016, 374, 1601-1604.	13.9	40
87	Legal and Policy Interventions to Improve Patient Safety. Circulation, 2016, 133, 661-671.	1.6	18
88	Should Malpractice Settlements Be Secret?. JAMA Internal Medicine, 2015, 175, 1135.	2.6	5
89	Searching for Public Health Lawâ€™™s Sweet Spot: The Regulation of Sugar-Sweetened Beverages. PLoS Medicine, 2015, 12, e1001848.	3.9	26
90	Medical Liability and Reporting Malpractice Paymentsâ€™™Reply. JAMA - Journal of the American Medical Association, 2015, 313, 1058.	3.8	2

#	ARTICLE	IF	CITATIONS
91	Half-Baked â€” The Retail Promotion of Marijuana Edibles. <i>New England Journal of Medicine</i> , 2015, 372, 989-991.	13.9	88
92	Shifting Vaccination Politics â€” The End of Personal-Belief Exemptions in California. <i>New England Journal of Medicine</i> , 2015, 373, 785-787.	13.9	68
93	Supporting Those Who Go to Fight Ebola. <i>PLoS Medicine</i> , 2015, 12, e1001781.	3.9	7
94	Institutional Oversight of Faculty-Industry Consulting Relationships in U.S. Medical Schools: A Delphi Study. <i>Journal of Law, Medicine and Ethics</i> , 2015, 43, 383-96.	0.4	5
95	How Policy Makers Can Smooth The Way For Communication-And- Resolution Programs. <i>Health Affairs</i> , 2014, 33, 11-19.	2.5	36
96	Tobacco 21 â€” An Idea Whose Time Has Come. <i>New England Journal of Medicine</i> , 2014, 370, 295-297.	13.9	39
97	What Is a Public Health â€œEmergencyâ€?. <i>New England Journal of Medicine</i> , 2014, 371, 986-988.	13.9	36
98	Making the Case for Health-Enhancing Laws after Bloomberg. <i>Hastings Center Report</i> , 2014, 44, 8-8.	0.7	3
99	Communication-And-Resolution Programs: The Challenges And Lessons Learned From Six Early Adopters. <i>Health Affairs</i> , 2014, 33, 20-29.	2.5	78
100	Implementing Hospital-Based Communication-And-Resolution Programs: Lessons Learned In New York City. <i>Health Affairs</i> , 2014, 33, 30-38.	2.5	25
101	Clinical Trials and the Right to Remain Silent. <i>JAMA Internal Medicine</i> , 2014, 174, 1505.	2.6	1
102	The Medical Liability Climate and Prospects for Reform. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2146.	3.8	75
103	A New Era in Noninvasive Prenatal Testing. <i>New England Journal of Medicine</i> , 2013, 369, 499-501.	13.9	93
104	Gene Patenting â€” The Supreme Court Finally Speaks. <i>New England Journal of Medicine</i> , 2013, 369, 869-875.	13.9	58
105	Breast Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2555.	3.8	16
106	A New Era in Noninvasive Prenatal Testing. <i>New England Journal of Medicine</i> , 2013, 369, 2164-2165.	13.9	18
107	Preparing for Responsible Sharing of Clinical Trial Data. <i>New England Journal of Medicine</i> , 2013, 369, 1651-1658.	13.9	155
108	Sunlight as Disinfectant â€” New Rules on Disclosure of Industry Payments to Physicians. <i>New England Journal of Medicine</i> , 2013, 368, 2052-2054.	13.9	63

#	ARTICLE	IF	CITATIONS
109	Talking with Patients about Other Clinicians' Errors. <i>New England Journal of Medicine</i> , 2013, 369, 1752-1757.	13.9	67
110	Defensive Medicine—Legally Necessary but Ethically Wrong?. <i>JAMA Internal Medicine</i> , 2013, 173, 1056.	2.6	21
111	Editors' Introduction. <i>Journal of Health Politics, Policy and Law</i> , 2013, 38, 629-643.	0.9	0
112	FDA Regulation of Off-label Drug Promotion Under Attack. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 445.	3.8	11
113	The Politics of HPV Vaccination Policy Formation in the United States. <i>Journal of Health Politics, Policy and Law</i> , 2013, 38, 645-681.	0.9	37
114	Critical Opportunities for Public Health Law: A Call for Action. <i>American Journal of Public Health</i> , 2013, 103, 1979-1988.	1.5	25
115	The Taxing Power and the Public's Health. <i>New England Journal of Medicine</i> , 2012, 367, 1777-1779.	13.9	2
116	Ethical Considerations in Studying Drug Safety — The Institute of Medicine Report. <i>New England Journal of Medicine</i> , 2012, 367, 959-964.	13.9	21
117	Ejecting trans fat from New York City restaurants. <i>Nature Reviews Endocrinology</i> , 2012, 8, 633-635.	4.3	1
118	Disclosure-And-Resolution Programs That Include Generous Compensation Offers May Prompt A Complex Patient Response. <i>Health Affairs</i> , 2012, 31, 2681-2689.	2.5	27
119	Pharmaceutical Companies'™ Role in State Vaccination Policymaking: The Case of Human Papillomavirus Vaccination. <i>American Journal of Public Health</i> , 2012, 102, 893-898.	1.5	37
120	Legal and policy approaches to the obesity epidemic. <i>Surgery for Obesity and Related Diseases</i> , 2012, 8, 507-513.	1.0	5
121	Disclosure, Apology, and Offer Programs: Stakeholders'™ Views of Barriers to and Strategies for Broad Implementation. <i>Milbank Quarterly</i> , 2012, 90, 682-705.	2.1	46
122	New horizons in pharmaceutical regulation. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 501-502.	21.5	8
123	Does Tort Law Improve the Health of Newborns, or Miscarry? A Longitudinal Analysis of the Effect of Liability Pressure on Birth Outcomes. <i>Journal of Empirical Legal Studies</i> , 2012, 9, 217-245.	0.5	23
124	New Directions in Medical Liability Reform. <i>New England Journal of Medicine</i> , 2011, 364, 1564-1572.	13.9	97
125	Medical Malpractice in the Military. <i>New England Journal of Medicine</i> , 2011, 365, 664-670.	13.9	3
126	Medical Malpractice Liability in the Age of Electronic Health Records. <i>Survey of Anesthesiology</i> , 2011, 55, 317-319.	0.1	3



#	ARTICLE	IF	CITATIONS
127	“Pay for Delay” Settlements of Disputes over Pharmaceutical Patents. <i>New England Journal of Medicine</i> , 2011, 365, 1439-1445.	13.9	23
128	Relationship between Quality of Care and Negligence Litigation in Nursing Homes. <i>New England Journal of Medicine</i> , 2011, 364, 1243-1250.	13.9	34
129	Restrictions on the Use of Prescribing Data for Drug Promotion. <i>New England Journal of Medicine</i> , 2011, 365, 1248-1254.	13.9	19
130	Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints. <i>PLoS Medicine</i> , 2011, 8, e1000431.	3.9	88
131	Administrative compensation for medical injuries: lessons from three foreign systems. <i>Issue Brief (Commonwealth Fund)</i> , 2011, 14, 1-18.	0.9	12
132	Malpractice Reform—Opportunities for Leadership by Health Care Institutions and Liability Insurers. <i>Obstetrics and Gynecology</i> , 2010, 116, 1254-1256.	1.2	0
133	Defensive Medicine and Tort Reform: A Wide View. <i>Journal of General Internal Medicine</i> , 2010, 25, 380-381.	1.3	30
134	Making the Case for Laws That Improve Health: A Framework for Public Health Law Research. <i>Milbank Quarterly</i> , 2010, 88, 169-210.	2.1	156
135	National Costs Of The Medical Liability System. <i>Health Affairs</i> , 2010, 29, 1569-1577.	2.5	409
136	Federal Trade Commission Regulation of Food Advertising to Children: Possibilities for a Reinvigorated Role. <i>Journal of Health Politics, Policy and Law</i> , 2010, 35, 227-276.	0.9	24
137	The Flaws In State “Apology” And “Disclosure” Laws Dilute Their Intended Impact On Malpractice Suits. <i>Health Affairs</i> , 2010, 29, 1611-1619.	2.5	69
138	The Havasupai Indian Tribe Case—Lessons for Research Involving Stored Biologic Samples. <i>New England Journal of Medicine</i> , 2010, 363, 204-207.	13.9	320
139	Regulation of Smoking in Public Housing. <i>New England Journal of Medicine</i> , 2010, 362, 2319-2325.	13.9	73
140	Whistle-Blowers' Experiences in Fraud Litigation against Pharmaceutical Companies. <i>New England Journal of Medicine</i> , 2010, 362, 1832-1839.	13.9	46
141	HPV Vaccination Mandates—Lawmaking amid Political and Scientific Controversy. <i>New England Journal of Medicine</i> , 2010, 363, 785-791.	13.9	90
142	Medical Malpractice Liability in the Age of Electronic Health Records. <i>New England Journal of Medicine</i> , 2010, 363, 2060-2067.	13.9	89
143	Gene Patenting—Is the Pendulum Swinging Back?. <i>New England Journal of Medicine</i> , 2010, 362, 1855-1858.	13.9	21
144	Malpractice Reform—Opportunities for Leadership by Health Care Institutions and Liability Insurers. <i>New England Journal of Medicine</i> , 2010, 362, 1353-1356.	13.9	43

#	ARTICLE	IF	CITATIONS
145	New York City's War on Fat. <i>New England Journal of Medicine</i> , 2009, 360, 2015-2020.	13.9	38
146	Disclosing Harmful Medical Errors to Patients. <i>Chest</i> , 2009, 136, 897-903.	0.4	35
147	Shifting Terrain in the Regulation of Off-Label Promotion of Pharmaceuticals. <i>New England Journal of Medicine</i> , 2009, 360, 1557-1566.	13.9	51
148	The Role of Medical Liability Reform in Federal Health Care Reform. <i>New England Journal of Medicine</i> , 2009, 361, 1-3.	13.9	185
149	Incremental Health Care Reform. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1814.	3.8	3
150	Commentary: A Legal Perspective on Diabetes Surveillance—Privacy and the Police Power. <i>Milbank Quarterly</i> , 2009, 87, 575-580.	2.1	1
151	Relationship Between Malpractice Litigation Pressure and Rates of Cesarean Section and Vaginal Birth After Cesarean Section. <i>Medical Care</i> , 2009, 47, 234-242.	1.1	175
152	RATIONALIZING VACCINE INJURY COMPENSATION. <i>Bioethics</i> , 2008, 22, 32-42.	0.7	24
153	A Longitudinal Analysis of the Impact of Liability Pressure on the Supply of Obstetrician-Gynecologists. <i>Journal of Empirical Legal Studies</i> , 2008, 5, 21-53.	0.5	26
154	Administrative Compensation of Medical Injuries: A Hardy Perennial Blooms Again. <i>Journal of Health Politics, Policy and Law</i> , 2008, 33, 725-760.	0.9	17
155	Obesity—personal choice or public health issue?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 2-3.	2.9	9
156	Wellness Programs and Lifestyle Discrimination — The Legal Limits. <i>New England Journal of Medicine</i> , 2008, 359, 192-199.	13.9	66
157	The Interplay of Public Health Law and Industry Self-Regulation: The Case of Sugar-Sweetened Beverage Sales in Schools. <i>American Journal of Public Health</i> , 2008, 98, 595-604.	1.5	74
158	Adjudicating Severe Birth Injury Claims in Florida and Virginia: The Experience of a Landmark Experiment in Personal Injury Compensation. <i>American Journal of Law and Medicine</i> , 2008, 34, 493-537.	0.5	16
159	Compact versus Contract — Industry Sponsors' Obligations to Their Research Subjects. <i>New England Journal of Medicine</i> , 2007, 356, 2737-2743.	13.9	14
160	Regulatory and Judicial Oversight of Nonprofit Hospitals. <i>New England Journal of Medicine</i> , 2007, 356, 625-631.	13.9	7
161	Sunshine Laws and the Pharmaceutical Industry. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1255.	3.8	17
162	Disclosure Of Medical Injury To Patients: An Improbable Risk Management Strategy. <i>Health Affairs</i> , 2007, 26, 215-226.	2.5	108

#	ARTICLE	IF	CITATIONS
163	Changes In Physician Supply And Scope Of Practice During A Malpractice Crisis: Evidence From Pennsylvania. <i>Health Affairs</i> , 2007, 26, w425-w435.	2.5	24
164	Geographic Variation in Informed Consent Law: Two Standards for Disclosure of Treatment Risks. <i>Journal of Empirical Legal Studies</i> , 2007, 4, 103-124.	0.5	29
165	Who Pays for Medical Errors? An Analysis of Adverse Event Costs, the Medical Liability System, and Incentives for Patient Safety Improvement. <i>Journal of Empirical Legal Studies</i> , 2007, 4, 835-860.	0.5	38
166	Claims, Errors, and Compensation Payments in Medical Malpractice Litigation. <i>New England Journal of Medicine</i> , 2006, 354, 2024-2033.	13.9	722
167	Liability, Patient Safety, and Defensive Medicine: What Does the Future Hold?. , 2006, , 93-114.		3
168	"Health Courts" and Accountability for Patient Safety. <i>Milbank Quarterly</i> , 2006, 84, 459-492.	2.1	58
169	Obesity " The New Frontier of Public Health Law. <i>New England Journal of Medicine</i> , 2006, 354, 2601-2610.	13.9	181
170	Medical-Process Patents " Monopolizing the Delivery of Health Care. <i>New England Journal of Medicine</i> , 2006, 355, 2036-2041.	13.9	16
171	THE ROLE OF CLINICAL GUIDELINES IN MEDICAL NEGLIGENCE LITIGATION: A SHIFT FROM THE BOLAM STANDARD?. <i>Medical Law Review</i> , 2006, 14, 321-366.	0.2	69
172	Effects of a Malpractice Crisis on Specialist Supply and Patient Access to Care. <i>Annals of Surgery</i> , 2005, 242, 621-628.	2.1	69
173	Managing Malpractice Crises. <i>Journal of Law, Medicine and Ethics</i> , 2005, 33, 414-415.	0.4	1
174	The Future of Surgery: Today's Residents Speak. <i>Journal of Surgical Education</i> , 2005, 62, 543-546.	0.7	16
175	Fostering Rational Regulation of Patient Safety. <i>Journal of Health Politics, Policy and Law</i> , 2005, 30, 375-426.	0.9	30
176	Defensive Medicine Among High-Risk Specialist Physicians in a Volatile Malpractice Environment. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2609.	3.8	957
177	Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry. <i>New England Journal of Medicine</i> , 2005, 352, 2202-2210.	13.9	121
178	Researchers' Views of the Acceptability of Restrictive Provisions in Clinical Trial Agreements with Industry Sponsors. <i>Accountability in Research</i> , 2005, 12, 163-191.	1.6	12
179	Legal Concerns and the Influenza Vaccine Shortage. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1817.	3.8	15
180	Effects of a Professional Liability Crisis on Residents' Practice Decisions. <i>Obstetrics and Gynecology</i> , 2005, 105, 1287-1295.	1.2	37

#	ARTICLE	IF	CITATIONS
181	The Pharmaceutical Industry versus Medicaid "Limits on State Initiatives to Control Prescription-Drug Costs. <i>New England Journal of Medicine</i> , 2004, 350, 608-613.	13.9	17
182	Financial Conflicts of Interest in Physicians' Relationships with the Pharmaceutical Industry "Self-Regulation in the Shadow of Federal Prosecution. <i>New England Journal of Medicine</i> , 2004, 351, 1891-1900.	13.9	198
183	Caring For Patients In A Malpractice Crisis: Physician Satisfaction And Quality Of Care. <i>Health Affairs</i> , 2004, 23, 42-53.	2.5	87
184	Medical malpractice as an epidemiological problem. <i>Social Science and Medicine</i> , 2004, 59, 39-46.	1.8	24
185	Decision making and satisfaction with care in the pediatric intensive care unit: Findings from a controlled clinical trial. <i>Pediatric Critical Care Medicine</i> , 2004, 5, 40-47.	0.2	20
186	The experience of a community representative on an ethics consult team. <i>Journal of Clinical Ethics</i> , 2004, 15, 296-301.	0.1	1
187	Conflict in the care of patients with prolonged stay in the ICU: types, sources, and predictors. <i>Intensive Care Medicine</i> , 2003, 29, 1489-1497.	3.9	192
188	Work hours reform: perceptions and desires of contemporary surgical residents. <i>Journal of the American College of Surgeons</i> , 2003, 197, 624-630.	0.2	96
189	Understanding Biased Selection in Medicare HMOs. <i>Health Services Research</i> , 2003, 38, 961-992.	1.0	79
190	Medical Monitoring for Pharmaceutical Injuries. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 889.	3.8	5
191	The McLawsuit: The Fast-Food Industry And Legal Accountability For Obesity. <i>Health Affairs</i> , 2003, 22, 207-216.	2.5	55
192	The Leapfrog Standards: Ready To Jump From Marketplace To Courtroom?. <i>Health Affairs</i> , 2003, 22, 46-59.	2.5	18
193	Hospitals' Behavior In A Tort Crisis: Observations From Pennsylvania. <i>Health Affairs</i> , 2003, 22, 225-233.	2.5	17
194	Direct-to-Consumer Advertising and Shared Liability for Pharmaceutical Manufacturers. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 477.	3.8	19
195	The New Medical Malpractice Crisis. <i>New England Journal of Medicine</i> , 2003, 348, 2281-2284.	13.9	211
196	Due Process in Investigations of Research Misconduct. <i>New England Journal of Medicine</i> , 2003, 349, 1280-1286.	13.9	23
197	Reduced Medicolegal Risk by Compliance With Obstetric Clinical Pathways. <i>Obstetrics and Gynecology</i> , 2003, 101, 751-755.	1.2	21
198	Results of a clinical trial on care improvement for the critically ill. <i>Critical Care Medicine</i> , 2003, 31, 2107-2117.	0.4	101

#	ARTICLE	IF	CITATIONS
199	Implementing Resident Work Hour Limitations. <i>Annals of Surgery</i> , 2003, 237, 449-455.	2.1	109
200	Nature of Conflict in the Care of Pediatric Intensive Care Patients With Prolonged Stay. <i>Pediatrics</i> , 2003, 112, 553-558.	1.0	141
201	Patient Safety and Medical Malpractice: A Case Study. <i>Annals of Internal Medicine</i> , 2003, 139, 267.	2.0	29
202	The Rise of Litigation in Human Subjects Research. <i>Annals of Internal Medicine</i> , 2003, 139, 40.	2.0	67
203	Policing Medicaid and Medicare Managed Care: The Role of Courts and Administrative Agencies. <i>Journal of Health Politics, Policy and Law</i> , 2002, 27, 465-494.	0.9	6
204	Do Medicare HMOs still reduce health services use after controlling for selection bias?. <i>Health Economics (United Kingdom)</i> , 2002, 11, 323-340.	0.8	83
205	Demystifying the Law/Science Disconnect. <i>Journal of Health Politics, Policy and Law</i> , 2001, 26, 429-438.	0.9	1